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Abstract
Purpose In phase I/II-studies radiolabelled ABY-025
Affibodymolecules identified human epidermal growth factor
receptor 2 (HER2) expression in breast cancer metastases
using PET and SPECT imaging. Here, we wanted to investi-
gate the utility of a simple intra-image normalization using
tumour-to-reference tissue-ratio (T/R) as a HER2 status dis-
crimination strategy to overcome potential issues related to
cross-calibration of scanning devices.
Methods Twenty-three women with pre-diagnosed HER2-
positive/negative metastasized breast cancer were scanned
with [111In]-ABY-025 SPECT/CT (n = 7) or [68Ga]-ABY-
025 PET/CT (n = 16). Uptake was measured in all metastases
and in normal spleen, lung, liver, muscle, and blood pool.
Normal tissue uptake variation and T/R-ratios were
established for various time points and for two different doses
of injected peptide from a total of 94 whole-body image ac-
quisitions. Immunohistochemistry (IHC) was used to verify
HER2 expression in 28 biopsied metastases. T/R-ratios were
compared to IHC findings to establish the best reference tissue
for each modality and each imaging time-point. The impact of
shed HER2 in serum was investigated.
Results Spleen was the best reference tissue acrossmodalities,
followed by blood pool and lung. Spleen-T/R was highly cor-
related to PET SUVinmetastases after 2 h (r = 0.96, P < 0.001)
and reached an accuracy of 100% for discriminating IHC
HER2-positive and negative metastases at 4 h (PET) and
24 h (SPECT) after injection. In a single case, shed HER2
resulted in intense tracer retention in blood. In the remaining
patients shed HER2 was elevated, but without significant im-
pact on ABY-025 biodistribution.
Conclusion T/R-ratios using spleen as reference tissue accu-
rately quantify HER2 expression with radiolabelled ABY-025
imaging in breast cancer metastases with SPECT and PET.
Tracer binding to shed HER2 in serum might affect quantifi-
cation in the extreme case.
Keywords Affibody . HER2-receptor . Shedding . PET .
SPECT . T/R
Introduction
Breast cancer is a disease of major socio-economic impor-
tance with a lifetime risk of 12% [1]. Strategic therapy deci-
sions and prognosis can be improved by subdividing the dis-
ease histologically. Immunohistochemistry (IHC) is used to
evaluate the expression of hormone receptors such as
oestrogen (ER), progesteron (PR), and the transmembrane re-
ceptors human epidermal growth factor 2 (HER2) [2].
Contrary to the first two, HER2 has no known natural ligand
and signals by hetero-dimerization with activated members of
HER family receptors [3]. Overexpression of HER2 has an
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incidence of 15-20% in breast cancer [4–6] and is associated
with poorer prognosis [4, 6]. Therapy using monoclonal anti-
bodies such as trastuzumab, pertuzumab, and more recently
the antibody-drug conjugate trastuzumab-emtansine improves
progression-free survival and overall survival of patients with
HER2-positive breast and gastroesophageal cancer [4, 6, 7].
Diagnosing HER2 receptor expression is crucial to identify
patients expected to benefit from treatment, as well as to avoid
unnecessary cost and potential risk of serious adverse effects
of treatment for patients with HER2-negative tumours.
Growing evidence of heterogeneous HER2 expression com-
plicates the clinical decision making, as immunohistochemis-
try (IHC) or in situ hybridization (ISH) analysis of the primary
tumour is unreliable as sole source of information in the met-
astatic setting [5, 8–11]. Current guidelines recommend biop-
sy with renewed IHC and/or ISH evaluation from at least one
metastasis before decision about further HER2-targeted ther-
apy [12]. Metastases may, however, not be easily available for
biopsy procedures. Biopsy sampling from metastases is, even
in the ideal case, associated with discomfort for the patient,
potential risk for infection and hemorrhage, and is for such
reasons sometimes omitted. Biopsy is generally guided by
morphological imaging methods like CT or ultrasound and
may miss the viable part of a tumour mass resulting in non-
representative and misleading information.
Radionuclide molecular imaging-based methods offer non-
invasive, whole body based diagnostics with minimal patient
discomfort while also being repeatable for monitoring of the
disease and therapy [13–15]. The use of radiolabelled thera-
peutic anti-HER2 antibodies as imaging agents is an obvious
possibility. However, intact antibodies have a slow blood
clearance and slow tumour penetration resulting in an optimal
imaging time point of 4-5 days after injection [14].
Furthermore, macromolecules accumulate in tumours due to
enhanced vascular permeability, irrespective of molecular tar-
get expression [16], potentially causing false-positive find-
ings. An alternative approach is to use radiolabelled HER2-
specific Affibody® molecules as imaging agents. Affibody
molecules are engineered scaffold peptides, which can be se-
lected for high affinity binding to a variety of proteinaceous
molecular targets [17]. The small molecular size (6-7 kDa
peptide) is fundamental for fast kinetics with rapid clearance
from both blood and tumours with low HER2-expression,
which is needed for high contrast imaging with limited radia-
tion dose using short-lived isotopes.
To be reliable, a HER2 imaging method should address two
issues, regardless of tracer choice. Firstly, only tumours with
HER2 expressionmatching 3+ staining by IHC or 2+ and ISH-
positive are considered as HER2-positive and would respond
to anti-HER2 therapy [2]. Tumours with lower expression
levels would not respond to the targeted therapy, but they
may contain tens or even hundreds of thousands HER2 recep-
tors per cancer cell [18] and might be detected by radionuclide
imaging [19]. Thus, the imagingmethod should reliably reflect
the receptor concentration to allow correct classification of a
HER2-negative tumour despite it also expressing the receptor
to some extent. Secondly, the shed form of the HER2 receptor
is present in the blood circulation with normal levels of serum-
HER2 lower than 15 μg/L. On occasion much higher values
can occur, primarily due to shedding from necrotic tumour
cells. In such cases, any HER2-specific molecule introduced
in the blood circulation might to some extent be trapped there
with the potential of altering its expected tissue distribution.
ABY-025 is a second generation HER2-binding Affibody
molecule with improved scaffold and reduced non-specific
liver uptake [20–22]. With high affinity for domain 3 of the
extracellular portion of the HER2 receptor it has the important
advantage of not competing for binding with trastuzumab
(domain 4) and pertuzumab (domain 2), permitting diagnostic
imaging during HER2-directed antibody therapy [23, 24].
In two recent phase I/II studies, ABY-025 was successfully
labelled with 111In for SPECT [23] and 68Ga for PET [24].
With both modalities, quantitative approaches were shown to
distinguish HER2-negative from HER2-positive metastases.
Figure 1 shows abdominal slices including spleen, liver, and
liver metastases from patients with breast cancer using 68Ga
PET and 111In SPECT at various time points after injection.
While the data from the previous small studies are encourag-
ing, there is a need to identify the simplest and most robust
quantitative approach before the subsequent multi-centre trials
in larger cohorts. The previously suggested SPECT/CT diag-
nostic method requires dual imaging at 4 and 24 h after injec-
tion for reliable HER2-status discrimination, which is logisti-
cally demanding in clinical routine. Ideally, SPECT/CT imag-
ing at one time-point should be adequate. With PETwe were
able to show that SUV-values correlated strongly with HER2
expression based on histopathology. PEToffers more accurate
quantification and simpler logistics using single-time-point
SUV measurements, compared to SPECT. However, use of
SUV as a universal reference requires identical calibration
between the scanner and well-counter equipment at various
medical centres. One approach for simplified image reading
and concordance among readers at different centres could be
to use intra-image measurement ratios by normalising meta-
static uptake to the uptake in an easily identifiable normal
tissue in order to establish a single time point tumour-to-
reference (T/R) ratio. This is a mainstream nuclear medicine
technique for establishing diagnostic thresholds, especially
with single photon methods. In addition to sub-optimal cam-
era calibration issues, this approach also reduces the impact of
many human errors such as mistyping patient weight, dose or
time of injection, partly extra-vasal injection and collimator
selection. The T/R concept accuracy depends on the inter-
individual reference tissue uptake variation, which might vary
with both imaging modality, time after injection, and amount
of cold peptide co-injected with radiolabeled peptide.
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In the context of imaging whole body HER2 expres-
sion there is also a need to evaluate the impact of poten-
tial binding to HER2 present in serum, as this could cause
higher tracer retention in blood and tissues with high
blood volume and impact the accuracy of T/R-ratios.
The aims of the study presented here thus was to re-
evaluate data from the two previous studies to investigate
1) the potential of a single time point T/R-ratio technique
for HER2 imaging using radiolabelled ABY-025 with
both SPECT and PET. 2) variation of biodistribution re-
lated to time after injection, peptide mass, and amount of
shed HER2 in serum.
Patients and methods
Protocol outline
Image data from 94 whole-body acquisitions in 23 patients
from two previous phase I studies [23, 24] were re-evaluated.
Common for both studies was an initial vertex to mid-thigh
[18F]-FDG PET/CT performed for baseline localization of vi-
able metastases, one to seven days prior to the examination
using radiolabelled ABY-025.
The first study applied SPECT/CT imaging in seven
patients using [111In]-ABY-025 [23]: A target dose of
150 MBq [111In]-ABY-025 was injected and SPECT/CT
of two individually selected regions of interest per patient,
e.g. thorax and abdomen, were recorded at 4, 24, and 48 h
after injection.
PET imaging using [68Ga]-ABY-025 [24]: This second
study was carried out in two phases. The first phase of ten
patients was performed to evaluate the impact of peptide mass
and scanning time on diagnostic efficacy and involved two
levels of injected ABY-025 dose (78 ± 8 μg and 427
± 19 μg) with whole body PET/CT at 1, 2, and 4 h after
injection. The second phase in six patients was a test-retest
measurement designed to calculate a repeatability coefficient
of lesional SUV by repeated exam with identical peptide dose
and scan time, both defined after analysing the first phase
results.
Detailed descriptions of radiochemistry are provided in
references [23, 24]. Briefly, GMP grade ABY-025 was
provided by Affibody AB in vials containing 100 μg.
For SPECT 100 μg of ABY-025 was labelled with
142.6 MBq (range 131-154 MBq) of 111In indium. For
PET, ABY-025 was labelled with 212 ± 46 MBq 68Ga gal-
lium and developed separately for low (LD: 78 ± 8 μg)
and high (HD: 427 ± 19 μg) ABY-025 peptide dose radio-
pharmaceuticals [25]. The radiochemical purity of the ra-
diopharmaceuticals was over 95%.
Blood samples for serum-HER2 analysis (Labor Limbach,
Heidelberg) were collected the day of the first radiolabelled
ABY-025 injection for all patients.
Fig. 1 Examples of abdominal PET/CT and SPECT/CT images
including normal liver, liver metastases and spleen for reference. Left
column: low peptide dose [68Ga]-ABY-025-PET/CT at 1, 2, and
4 hours after injection. Middle column: high peptide dose [68Ga]-ABY-
025-PET/CT at corresponding time points in the same patient. Right
column (other patient): [111In]-ABY-025–SPECT/CT at 4, 24, and
48 hours after injection. The PET colour scale is thresholded at SUV
32. The SPECT images are corrected for the decay of 111In to represent
uptake and the colour scale arbitrarily normalised. Arrows indicate a liver
metastasis of breast cancer in each of the two patients. Examples of dual
spleenVOI:s (spherical) and single slice circular ROI are shown in yellow
(first row PET images). 68Ga LD and 68Ga HD stand respectively for low
and high peptide content [68Ga]-ABY-025. 111In stands for [111In]-ABY-
025
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Patients
A total of 23 women with known metastatic breast cancer
were included (111In SPECT: n = 7, 68Ga PET: n = 16).
Potential participants were previously diagnosed with meta-
static breast cancer and had known HER2 classification of the
primary tumour (HER2-positive: HercepTest score 3+ or
HercepTest score 2+ and ISH-positive; HER2-negative:
HercepTest score 0 or 1+, or score 2+, but ISH-negative).
On-going treatment, HER2-targeted or other, was not an ex-
clusion criterion and planned medication was given as pre-
scribed throughout the studies. Patient characteristics are sum-
marized in Table 1. Biopsies for IHC and ISH were per-
formed, guided by CT or ultrasound, when considered clini-
cally relevant and tolerated by the patient. A total of 16 biop-
sies were obtained during the PET study and 12 during the
SPECT study. IHC and ISH results were summarised as
HER2-scores as described above. Details regarding handling
of biopsy specimens have been published previously [23, 24].
The original studies were academically sponsored clinical
trials (trial identifiers [111In]-ABY-025: EudraCT 210-
021078-12 and NCT01216033; [68Ga]-ABY-025: EudraCT
2012-005228-14 and NCT01858116), approved by the re-
gional ethics committee and the Swedish Medical Products
Agency. All patients signed informed consent.
Image acquisition protocols
SPECT/CT (GE Infinia, GE Healthcare, Waukesha, WI,
USA) was performed at 4, 24, and 48 h. At each time
point two SPECT/CT scans were performed covering
body parts selected from the metastatic findings in the
initial [18F]FDG-PET/CT, typically one thoracic and one
abdominal position. SPECT images were corrected for
attenuation using simultaneously acquired low-dose CT,
using manufacturer’s settings.
PET/CT (GE Discovery STE, GE Healthcare, Waukesha,
WI, USA) was acquired by whole-body imaging from vertex
to mid-thigh. All PET images underwent all relevant correc-
tions according to the manufacturer’s recommendations.
Fifteen out of 16 patients in the PET-study were scanned
twice, 1 week apart. For the first ten patients, LD [68Ga]-
ABY-025 PET preceded HD [68Ga]-ABY-025 PET to mini-
mize the potential effects of prolonged peptide binding to
target on the subsequent scan. These ten patients were scanned
at 1 h, 2 h, and 4 h after injection to study biodistribution. Five
patients were scanned twice with HD PET for test-retest pur-
poses and were scanned only at 2 h after injection. One patient
included in the test-retest experiment only underwent the first
HD PET.
Image evaluation and SUV calculations
[18F]FDG-PET/CT data were analysed for metastatic lesions
according to routine clinical criteria by experienced observers,
supported by additional imaging from various modalities
when needed. Guided by findings from [18F]FDG-PET/CT,
subsequent radiolabelled ABY-025 images were analysed for
lesional uptake, which was measured as maximum voxel val-
ue. Normal tissue uptake was measured as mean of as-large-
as-possible spherical VOI:s in spleen, liver, kidney, blood pool
(mediastinal aorta and left ventricular cavity), muscle (erector
spinae, gluteal, and shoulder), fat (subcutaneous and abdom-
inal), and lung (dorsal, mid, and ventral). VOI values were
averaged with one from each side for paired organs (three
for the kidneys), three for the liver, two for spleen and aortic
blood pool, and one for the cardiac blood pool. The spleen
was also evaluated using a simple circular single-ROI mea-
surement. PET measurements were converted to SUV.
For SPECT images, the attenuation corrected count values
were used. When possible, the reference region was measured
in the same SPECT volume because of variations in back-
ground scatter between the volumes. Scatter was generally
higher in the volume closest to the kidneys. No normalization
was applied when lesion and reference had to be measured in
Table 1 Patient characteristics
for PET [24] and SPECT [23]
studies










Median age in years
(range)
50 (41-74) 65 (33-74) 0.43 57 (46-69) 66 (65-70) 0.21
Height (cm) 164 ± 8 165 ± 6 0.83 166 ± 5 165 ± 9 0.86
Weight (kg) 70 ± 14 64 ± 14 0.46 82 ± 3 66 ± 16 0.4
HER2-targeted treatment 8 3 0.065 4 1 0.12
[18F]FDG-PET/CT
metastases/patient
6 ± 3 8 ± 2 0.28 13 ± 8 (65 ± 17) 0.057
Analysed biopsies 7 9 0.29 4 8 1
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separate volumes, as this procedure would in itself also intro-
duce a potential error source.
Statistics
Values are reported as mean ± standard deviation (SD), unless
otherwise specified. Coefficient of variation (%CV) was cal-
culated as SD/mean. Comparisons of different settings (LD
[68Ga]-ABY-025 versus HD [68Ga]-ABY-025, [18F]FDG vs.
radiolabelled ABY-025 counterparts, HER2-positive vs.
HER2-negative were assessed using the Wilcoxon rank sum
test. Correlations of T/R-ratios towards SUV (PET), 24 h/4 h
uptake ratios (SPECT dual time-point method) and HER2-
scores were calculated using Spearman’s rank. A P < 0.05
was considered statistically significant.
Results
Protocol compliance
Twenty-two patients performed all scans according to the pro-
tocol. Patient 12 in the 68Ga-PET/CT study (PET#12) was
recruited to the test-retest paradigm but the retest scan was
cancelled because no viable metastases were detected by the
initial [18F]FDG -PET and [68Ga]-ABY-025 scans. Patient
clinical data is summarized in Table 1.
Biopsies, IHC, and HER2-status in metastases
A total of 28 biopsies from 18 patients were confirmed to be
metastases of breast cancer and stained for HER2-status.
Remaining patients either declined biopsy or the clinical in-
centive was considered too weak.
Serum-HER2 analysis
Patient PET#12 was a clear outlier with serum-HER2 of
1276 μg/L (Normal: < 15 μg/L) [26]. The high level of shed
HER2 correlated clearly with prolonged retention of radioac-
tivity in circulation and elevated uptake in normal tissues, see
Fig. 2. Excluding patient PET#12 from analyses serum-HER2
in the PET cohort was 30 ± 18 (range 11-80) μg/L and in the
SPECT cohort 32 ± 17 (range 8.6-56) μg/L. Serum-HER2 did
not correlate with blood pool measurements.
Coefficient of variation
The data concerning coefficient of variation (%CV) are pre-
sented in Table 2. In both studies, the lowest tissue %CV was
found for spleen (VOI) and kidney (three VOIs each), the
latter with the highest accumulated tissue activity. Other ex-
amples of low %CV were cardiac blood pool and muscle
followed by liver, lung, and aortic blood pool.
Tissues prone to metastases from breast cancer could be
problematic for use as reference tissue. All visible metastases
where cautiously avoided in these measurements. Bone
Fig. 2 (a): Maximum intensity projection (MIP) example of
extraordinary shedding after start of HER2-targeted therapy (PET#12)
at 2 h after injection (the only available time point in this case). (b): Bar
graph of the SUV for this patient’s tissues relative the average of all 16
patients at the corresponding time point. Highest value (370%) was found
for the aortic blood pool, with 260% for cardiac blood pool (partly
myocardium). Notably, a tilted distribution of activity towards blood
and blood rich organs and away from kidney, muscle and liver was
seen. (c): For comparison, a MIP of a patient with HER2-positive
metastases in liver and bone marrow, but no visible activity in the blood
at 2 h. This pattern was seen in 22/23 patients in both ABY-025 studies
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marrow was excluded from analyses because of high degree
of metastasizing in multiple patients.
[18F]FDG -PET/CT
[18F]FDG PET/CT detected at least two lesions per patient in
both studies. The difference between [18F]FDG SUVs for
HER2-positive and negative lesions was not statistically sig-
nificant either in the PET (P = 0.11) or SPECT study (P = 0.8)
making tumour-to-reference calculations for HER2-
expression irrelevant for [18F]FDG.
Tumour-to-reference tissue (T/R) ratio
All the studied reference tissues were evaluated regarding their
capacity for discriminating HER2-positive from HER2-
negative metastases using the T/R approach (see Table 2).
Actual reference tissue values for [68Ga]-ABY-025 PET are
summarized in supplementary table 1. T/R-values of metastatic
[111In]-ABY-025 SPECT voxel max to reference tissue mean
were significantly different between biopsy-verified HER2-
positive and negative metastases (P = 0.016) for all time points
(4 h, 24 h, and 48 h) using spleen, muscle, or lung as reference
tissue. This pattern was similar with [68Ga]-ABY-025 PET,
with all combinations of time point and peptide dose using
spleen, spine muscle, or liver as reference tissue (P-value
range: 0.002-0.041). T/R-values for blood pool and several
other tissues were likewise significant at various combinations
of modality and time points. Non-significant T/R-values were
most frequently seen in the earliest (1 h) PET acquisition and
mainly when a low peptide amount was injected. The cardiac
blood pool evaluation was the better choice with PET com-
pared to aortic measurement (not performed for SPECT).
The best reference tissue in both modalities was spleen. T/
R using spleen correlated well with IHC HER2-scores for
both [68Ga]-ABY-025 PET (at 2 h: n = 16, r = 0.84, P <
0.001; at 4 h: n = 12, r = 0.93, P < 0.001) and [111In]-ABY-
025 SPECT (at 24 h: n = 7, r = 0.80, P < 0.01; 48 h: n = 7,
r = 0.85, P < 0.01). T/R using spleen also correlated with
[68Ga]-ABY-025 PET SUVs (2 h: n = 16, r = 0.94, P <
0.001; at 4 h: n = 12, r = 0.96, P < 0.001).
Suitable spleen T/R cut-off levels for lesional HER2-status
discrimination were identified as 2.0 for [111In]-ABY-025
SPECT at 24 and 48 h, and 2.75 for [68Ga]-ABY-025 PET at
2 h and 6.5 at 4 h. These cut-off values had accuracies >95% for
discriminating IHC HER2-positive and negative metastases.
[68Ga]-ABY-025 T/R reproducibility: test-retest
Five patients completed both scans in the test-retest phase of the
[68Ga]-ABY-025 PET/CT study and were scanned using near
identical radioactivity and HD peptide doses with whole-body
Table 2 Coefficient of variation
(%CV) for tissue measurements
with [68Ga]-ABY-025 PET in
relation to injected peptide mass
and time after tracer injection, and
[111In]-ABY-025-SPECT in
relation to time after tracer
injection
[68Ga]-ABY-025 PET [111In]-ABY-025 SPECT





















Spleen (VOI) 17* 18* 28** 16* 17** 19*** 19* 31* 28*
Spleen (ROI) 21* 23** 27* 20** 18** 22***
Lung (ventral) 42 39* 38*** 33* 35** 35*** 28 28* 31*
Lung (hilus
level)
45 40 34*** 28* 32** 29*** 39 40* 45*
Lung (dorsal) 37 33* 31*** 25* 30** 32*** 32 38* 37*
Liver 30* 34* 30** 31* 33** 27*** 31* 28* 27*
Kidney 20 19* 17* 16* 18* 26** 15 19* 18*
Shoulder
muscle
25 31 20* 29* 19* 30* 18* 21* 24*
Dorsal spine
muscle
53* 60** 35* 57* 52* 44** 10* 19* 24*
Gluteus muscle 40 38 35 35 35 35**
Blood pool,
heart
36 25* 14** 25* 18* 16* 15* 31* 19*
Blood pool,
aorta
41 33 25* 37 33 28***
Visceral fat 58* 34* 71*** 53* 57 63***
Subcutaneous
fat
49 40 44* 48 48 43** 12* 22* 19*
Cerebellum 30* 30** 40** 21* 24* 43**
Cerebrum 28 21* 25* 26* 26* 33**
P-values for correlation of HER2-diagnostics with T/R and the specified tissue as reference, against biopsy
analysis results for each time and dose combination coded as: * = P < 0.05, ** = P < 0.01, *** = P < 0.005
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imaging 2 h after injection one week apart. Each patient had at
least two breast cancer metastases identified by [18F]FDG-PET
and measurable in both [68Ga]-ABY-025 PET scans. Mean
splenic SUVmean with 3D-VOI was 1.7 ± 0.3 at both examina-
tions (P = 0.99). T/R highly and linearly correlatedwith SUVmax
for the ten metastases using both the mean of two 3D-VOI:s and
a single circular 2D-ROI for defining spleen uptake (r > 0.97,
P < 0.001 for all correlations). The repeatability coefficients of
T/R (spleen) were 2.9 (15%) for the 3D-VOI and 3.3 (19%) for
the 2D-ROI (P = 0.46). The data is presented in Table 3.
Discussion
The present study investigated the feasibility of using
tumour-to-reference tissue SUV ratio values obtained
from whole-body HER2-imaging for standardizing the
quantitative discrimination between HER2-positive and
negative lesions. Data from clinical studies conducted pre-
viously in breast cancer patients using [68Ga]-ABY-025
PET/CT and [111In]-ABY-025 SPECT were used for the
assessment of relevant reference tissues. For both modal-
ities, several tissues were identified as potentially rele-
vant. Using the spleen as reference tissue resulted in ac-
curate discrimination of HER2-positive and negative
breast cancer metastases with both modalities, see
Fig. 3a and b. Using PET, the spleen T/R was associated
with test-retest reproducibility similar to SUVs. This
could become of value in multi-centre studies and clinical
routine, if verified in larger patient cohorts.
The major criteria for the selection of a reference tissue
were: 1) correlation with biopsy analysis results; 2) low
Fig. 3 (a) HD [68Ga]-ABY-025 PETat 4 h after injection: Scatter plot of
spleen T/R against SUV. Suggested cut off for T/R-based HER2-
diagnostics using these criteria is 6.5. At 2 h after injection the
distribution was similar, but with a suggested cut off of 2.75 with one
false positive (HercepTest 2+/ISH negative) metastasis, correctly
classified here at 4 h. (b) [111In]-ABY-025 SPECT at 24 h after
injection. Scatter plot of spleen T/R against the previously described 24/
4 h uptake ratio (dual time point) method. Suggested cutoff of 2 for
HER2-diagnostics using these criteria. All data points represent
metastases with HER2-status verified by immunohistochemistry. Red
circles: HER2 negative, blue squares: HER2-positive. Blue arrow:
actual T/R-value of 27.3
Table 3 Reproducibility of
tumour to reference tissue ratios
(T/R) for [68Ga]-ABY-025 PET
high peptide dose at 2 hours after
injection using various reference
tissues








Spleen (dual VOI) 8.5 ± 6.7 8.1 ± 7.0 0.74 2.90 14.6%
Spleen (simple
ROI)
8.4 ± 6.6 8.6 ± 6.8 0.91 3.34 18.7%
Lung (ventral) 20.4 ± 18.6 20.1 ± 17.8 0.85 5.34 20.1%
Lung (hilus level) 20.9 ± 17.4 21.0 ± 17.0 0.91 5.01 16.4%
Lung (dorsal) 16.0 ± 12.0 15.8 ± 13.0 0.80 3.81 17.2%
Liver 3.2 ± 3.0 2.7 ± 2.1 0.91 1.72 24.0%
Kidney 0.42 ± 0.41 0.39 ± 0.36 0.74 0.222 28.2%
Blood pool (heart) 5.6 ± 4.6 5.4 ± 3.9 0.97 2.06 12.3%
Blood pool (aorta) 8.1 ± 6.0 8.8 ± 6.8 0.80 3.40 24.4%
Shoulder muscle 27.9 ± 25.3 25.0 ± 19.5 0.97 12.2 13.2%
Dorsal spine
muscle
31.0 ± 22.2 29.8 ± 20.2 0.80 11.4 23.1%
Gluteal muscle 25.5 ± 22.5 25.5 ± 21.1 0.91 5.26 16.9%
Visceral fat 59.1 ± 75.3 45.3 ± 57.9 0.48 34.3 25.9%
Subcutaneous fat 74.9 ± 51.3 78.2 ± 48.8 0.97 18.6 29.7%
Cerebellum 122 ± 118 84.9 ± 66.1 0.53 135 26.9%
Cerebrum 246 ± 208 460 ± 792 0.91 1597 114%
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variation of radioactivity uptake; 3) low probability of
hosting metastases from breast cancer. Spleen was the
best reference tissue for both modalities. A single circular
ROI positioned centrally in the spleen was sufficient for
calculating accurate and reproducible T/R-values in the
current data sets. Additional tissues, such as spine muscle,
lung and blood pools, could be used as alternative refer-
ence tissues, for instance in splenectomised patients.
Uptake in spleen was in between the two blood pool
curves and at 2 h basically the mean of these. The wash
out was, however, slower for spleen than blood and even
slower for lung tissue. As reference tissue, spleen, and
lung could be viewed as two differently low-pass-filtered
versions of the blood signal. Measurements in tissues like
spleen and lung are also simpler to perform reliably than
measurements in the heart, which is a moving organ, or
the aorta which has somewhat limited diameter and po-
tential variations in exact location between the CT and
NM acquisition. Solid organs also generally seem less
affected by shed HER2 than the blood pool itself.
Undetected micrometastases present in the reference tis-
sue might, however, result in aberrantly high values, in-
creasing the risk of a false negative T/R value. Tissues not
prone to metastases from breast cancer, therefore, appear
like a safer choice, given that the other factors are equal.
Potential for such micrometastases argues against liver
and lung, which are otherwise convenient as reference
tissue and with encouraging results for the analysed data
sets.
Binding of ABY-025 to shed HER2 in blood might
influence biodistribution and change the result of any
method using a tissue uptake as reference. High correla-
tion between serum-HER2 and the reference tissue uptake
would indicate higher risk of diagnostic errors since high
(or low) serum-HER2 cannot reliably predict the HER2-
status of an individual metastatic lesion. However, serum-
HER2 had minimal impact on reference tissue measure-
ments, when the single outlier PET#12 was removed from
the analysis. This patient underwent surgery for a HER2-
positive breast cancer two months prior to PET. One
month later she was diagnosed with massive liver metas-
tasis and started treatment with trastuzumab, pertuzumab,
and docetaxel. She was included into the test-retest arm of
the PET project, where scanning with [18F]FDG-PET,
[68Ga]-ABY-025 PET and diagnostic CT showed dramatic
shrinkage of liver dimensions and absence of viable me-
tastases. Serum-HER2 at the time of scanning was almost
one hundred times higher than the normal upper limit.
Liver biopsy after PET examination showed fibrosis and
no sign of remaining cancer cells. As can be seen from
Fig. 2a, [68Ga]-ABY-025 retention in the blood pool was
very intense, resembling an angiogram. The very high
serum-HER2 was associated with lower SUV in kidney,
liver and muscles and higher SUV in lung, fat, spleen, and
blood, which was most elevated of all tissues (Fig. 2b).
The interpretation was that on-going treatment had exe-
cuted a rapid cytotoxic impact on the metastases with
HER2 debris leaking into the blood stream. [68Ga]-ABY-
025 apparently identifies shed HER2 as intact HER2,
resulting in increased intravascular binding in such cir-
cumstances. In the current context this patient was there-
fore considered an outlier. At follow-up 2 years after PET
she was still in complete remission. From this single case
observation it seems obvious that extremely high serum-
HER2 levels can result in altered distribution of [68Ga]-
ABY-025 amongst the normal tissues. On the other hand,
serum-HER2 levels up to almost six times higher than the
normal limit, as observed among the other 15 patients, did
not correlate with SUV in the blood pool and did not
affect the organ distribution.
The diagnostic capability of HER2 imaging using ABY-025
has previously been reported for both SPECT and PET. SUV
measurements are subject to errors originating from equipment
cross-calibration and data handling variation. Any selected cut-
off level might carry a risk of not being fully compatible across
sites and scanner models [27–29]. For multicentre studies and
for daily clinical routine, a methodology independent of abso-
lute SUV levels, based only on intra-image references, offers a
simpler, more standardized and theoretically less error-prone
alternative. Intra-image ratios inherently compensate for decay,
administered dose and distribution volume. This was the reason
why a T/R scheme was preferred over SUV for FDG PET-
classification of lymphomas [29].
For SPECT such reference tissue-based methodologies are
common because of even greater methodological difficulties
to achieve absolute quantification. Examples for SPECT in-
clude heart-to-mediastinal ratio (H/R) in [123I]-MIBG
neurocardiac imaging [30] and the Krenning scale (tumour-
to-liver ratio) for [111In]-octreoscan scintigraphy [31].
If prospectively verified in subsequent clinical studies
using radiolabelled ABY-025 for both PET and SPECT, a
tumour-to-reference ratio using spleen, blood pool, or lung
tissue might be an effective and simple approach for assessing
tumour HER2 expression.
Conclusion
Intra-image normalization of tumour-to-spleen uptake provides
a simple and robust semi-quantification of HER2 expression for
SPECT and PET. The diagnostic capability of spleen T/R for
discriminating HER2-positive from negative breast cancer me-
tastases was equivalent to the previously described ABY-025
methods: dual-time-point method for SPECT and SUV for
PET. This simplified approach could facilitate clinical
Eur J Nucl Med Mol Imaging
dissemination. Shedding may present diagnostic problems in
the rare case with extremely high serum-HER2.
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